CHRS
Coherus Biosciences Inc

5,167
Mkt Cap
$261.08M
Volume
1.8M
52W High
$2.62
52W Low
$0.71
PE Ratio
-1.37
CHRS Fundamentals
Price
$2.17
Prev Close
$2.16
Open
$2.14
50D MA
$1.51
Beta
1.84
Avg. Volume
3.41M
EPS (Annual)
$0.2482
P/B
2.87
Rev/Employee
$1.17M
Loading...
Loading...
News
all
press releases
Registration-Ready: How 2026's Clinical Leaders Are Beating Cancer Benchmarks
Registration-Ready: How 2026's Clinical Leaders Are Beating Cancer Benchmarks Registration-Ready: How 2026's Clinical Leaders Are Beating Cancer Benchmarks PR Newswire VANCOUVER, BC, Jan. 27, 2026...
PR Newswire·7d ago
News Placeholder
More News
News Placeholder
Coherus Oncology Sees Unusually Large Options Volume (NASDAQ:CHRS)
Coherus Oncology, Inc. (NASDAQ:CHRS - Get Free Report) was the recipient of some unusual options trading on Friday. Stock traders bought 2,341 call options on the stock. This represents an increase...
MarketBeat·11d ago
News Placeholder
Coherus Oncology, Inc. (NASDAQ:CHRS) Given Consensus Recommendation of "Hold" by Analysts
Shares of Coherus Oncology, Inc. (NASDAQ:CHRS - Get Free Report) have received a consensus rating of "Hold" from the five analysts that are currently covering the firm, Marketbeat Ratings reports...
MarketBeat·11d ago
News Placeholder
Coherus Oncology (NASDAQ:CHRS) Share Price Passes Above 200-Day Moving Average - Here's Why
Coherus Oncology (NASDAQ:CHRS) Share Price Passes Above Two Hundred Day Moving Average - Should You Sell...
MarketBeat·17d ago
News Placeholder
Functional Force: Precision Platforms Disrupt the 2026 Tumor Landscape
Functional Force: Precision Platforms Disrupt the 2026 Tumor Landscape Functional Force: Precision Platforms Disrupt the 2026 Tumor Landscape PR Newswire VANCOUVER, BC, Jan. 16, 2026 Issued on behalf...
PR Newswire·18d ago
News Placeholder
Ascendis Pharma (ASND) Surges 3.0%: Is This an Indication of Further Gains?
Ascendis Pharma (ASND) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Zacks·20d ago
News Placeholder
Coherus Oncology (NASDAQ:CHRS) Share Price Passes Above 200 Day Moving Average - Should You Sell?
Coherus Oncology (NASDAQ:CHRS) Stock Crosses Above 200 Day Moving Average - Should You Sell...
MarketBeat·1mo ago
News Placeholder
Coherus Oncology (NASDAQ:CHRS) Stock Crosses Above Two Hundred Day Moving Average - Here's What Happened
Coherus Oncology (NASDAQ:CHRS) Share Price Passes Above Two Hundred Day Moving Average - Here's What Happened...
MarketBeat·1mo ago
News Placeholder
Coherus Oncology (NASDAQ:CHRS) Stock Price Crosses Above 200 Day Moving Average - Here's Why
Coherus Oncology (NASDAQ:CHRS) Share Price Crosses Above Two Hundred Day Moving Average - What's Next...
MarketBeat·2mo ago
News Placeholder
Coherus Oncology, Inc. (NASDAQ:CHRS) Given Average Rating of "Hold" by Brokerages
Shares of Coherus Oncology, Inc. (NASDAQ:CHRS - Get Free Report) have earned a consensus recommendation of "Hold" from the five ratings firms that are covering the firm, MarketBeat.com reports. One...
MarketBeat·2mo ago
<
1
2
...
>

Latest CHRS News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.